Abstract
Antimicrobiological and clinical effects of DL-8280 were investigated and the following results were obtained.
Antimicrobiological effect: MIC80 against clinically isolated Staphylococcus and Streptococcus faecalis was 0.78 μg/ml and this value was superior to that of NFLX. MICs against gram negative bacteria were 0.10 μg/ml for Escherichia coli and Klebsiella pneumoniae, 0.20 μg/ml for Proteus, 3.13 μg/ml for Serratia, 0.39 μg/ml for Citrobacter freundii and these values were almost the same to NFLX and superior to those of PPA and AMPC.
Clinical effect: DL-8280 was administered to 23 patients of respiratory tract infection, 12 patients of urinary tract infection and 6 patients of intestinal tract infection in a total of 41 patients. The results showed 6 cases of excellent, 26 cases of good, 8 cases of fair and poor, 1 case of unevaluable and the effective rate was 80%. As a side effect, 1 case with diarrhea and stomach discomfort, 1 case with anorexia and bitter taste and 1 case with vertigo were observed. Laboratory examinations revealed 1 case with an increase in S-GOT and S-GPT, 1 case with an increase in S-GPT, 1 case with an increase in the number of eosinophil but these were slight.
From these results, it was concluded that DL-8280 is a useful drug for the treatment of respiratory tract infection, urinary tract infection and intestinal tract infection.
